Drug Trial Radar · NCT07491445
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Mar 9, 2026
Primary completion
Apr 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- Revolution Medicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Conditions
- Pancreatic Cancer
- Pancreatic Cancer Metastatic
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Adenocarcinoma
- Pancreatic Adenosquamous Carcinoma
Interventions
daraxonrasibDrug
oral tablets
gemcitabineDrug
intravenous (IV) infusion
nab-paclitaxelDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS) as assessed by blinded independent central review (BICR)Time frame: Up to approximately 2 years
- Overall survival (OS)Time frame: Up to approximately 2 years
Locations
106 sites in 21 countries. Site status is shown where the registry gives one.
Mayo Clinic - Scottsdale
Phoenix, Arizona · Active not recruiting
Honor Health Research Institute
Scottsdale, Arizona · Active not recruiting
University of California Los Angeles Health - Hematology/Oncology
Los Angeles, California · Active not recruiting
University of California San Francisco
San Francisco, California · Active not recruiting
Mayo Clinic Cancer Center- Florida
Jacksonville, Florida · Active not recruiting
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida · Active not recruiting
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland · Active not recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Active not recruiting
Henry Ford Health System
Detroit, Michigan · Active not recruiting
Mayo Clinic Cancer Center- Rochester
Rochester, Minnesota · Active not recruiting
Comprehensive Cancer Centers of Nevada
Henderson, Nevada · Active not recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Active not recruiting
Duke University Medical Center
Durham, North Carolina · Active not recruiting
University of Cincinnati Cancer Center
Cincinnati, Ohio · Active not recruiting
Taylor Cancer Research Center
Maumee, Ohio · Active not recruiting
SCRI Oncology Partners
Nashville, Tennessee · Active not recruiting
SCRI - Texas Oncology Dallas
Dallas, Texas · Active not recruiting
MD Anderson Cancer Center
Houston, Texas · Active not recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Active not recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Active not recruiting
Virginia Mason Medical Center
Seattle, Washington · Active not recruiting
St. George Hospital
Kogarah, New South Wales, Australia · Recruiting
Prince of Wales Hospital
Randwick, New South Wales, Australia · Recruiting
GenesisCare St Leonards
Saint Leonards, New South Wales, Australia · Recruiting
Calvary Mater Newcastle
Waratah, New South Wales, Australia · Recruiting
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia · Recruiting
Epworth HealthCare
East Melbourne, Victoria, Australia · Recruiting
Austin Health, Olivia Newton-John Cancer Research & Wellness Centre
Heidelberg, Victoria, Australia · Recruiting
Krankenhaus Barmherzige Schwestern Linz
Linz, Austria · Recruiting
Krankenhaus der Barmherzigen Brüder Wien-Klinisch wissenschaftliche Studien
Vienna, Austria · Recruiting
Institut Jules Bordet
Anderlecht, Belgium · Recruiting
Imeldaziekenhuis
Bonheiden, Belgium · Recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
Universitair Ziekenhuis Brussel
Jette, Belgium · Recruiting
UZ Leuven (Univ Ziekenhuis Leuven)
Leuven, Belgium · Recruiting
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
São Paulo, Brazil · Recruiting
CEPON - Centro de Pesquisa Oncologicas de Santa Catarina
Florianópolis, Santa Catarina, Brazil · Recruiting
Centre Hospitalier de l'Université de Montréal (CHUM)
Québec, Montreal, Canada · Recruiting
Sunnybrook Research Institute
Toronto, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.